Literature DB >> 17158640

Hodgkin's lymphoma associated T-cells exhibit a transcription factor profile consistent with distinct lymphoid compartments.

Cigdem Atayar1, Anke van den Berg, Tjasso Blokzijl, Marcel Boot, Randy D Gascoyne, Lydia Visser, Sibrand Poppema.   

Abstract

BACKGROUND: Hodgkin's lymphoma (HL) is characterised by an ineffective immune response that is predominantly mediated by CD4+ T-cells. AIMS: To analyse the expression of the key regulatory T-cell transcription factors (TFs) in the T-cells of HL involved tissues in order to assess the nature of the T(H) immune response in HL. METHODS AND
RESULTS: By immunohistochemistry, GATA3 was strongly and T-bet exclusively expressed in a subset of interfollicular lymphocytes in the reactive lymphoid tissues. In classical HL (CHL), which is generally located in the interfollicular zones, a predominance of T-bet+ T-cells and lesser amounts of GATA3+ and c-Maf+ T-cells was found, concordant with the pattern of the normal interfollicular compartment. In reactive lymphoid tissues, c-Maf was observed mostly in T-lymphocytes within the germinal centres (GCs). Nodular lymphocyte predominance type of Hodgkin's lymphoma (NLPHL) and progressively transformed germinal centres cases, showed a majority of c-Maf+ T-cells, consistent with the pattern in normal GCs. NLPHL cases uniformly showed c-Maf+/CD57+ T-cell rosettes around the neoplastic cells; these rosettes were absent in "paragranuloma-type" T-cell/histiocyte rich B-cell lymphoma.
CONCLUSIONS: T-cell TF expression profiles of the reactive T-cells in both subtypes of HL are in accordance with the expression profile observed in the distinct lymphoid compartments.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17158640      PMCID: PMC2014845          DOI: 10.1136/jcp.2006.044222

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  33 in total

Review 1.  Cellular origin of nodular lymphocyte-predominant Hodgkin's lymphoma: immunophenotypic and molecular studies.

Authors:  W C Chan
Journal:  Semin Hematol       Date:  1999-07       Impact factor: 3.851

2.  T-bet, a T cell-associated transcription factor, is expressed in Hodgkin's lymphoma.

Authors:  David M Dorfman; Eun Sook Hwang; Aliakbar Shahsafaei; Laurie H Glimcher
Journal:  Hum Pathol       Date:  2005-01       Impact factor: 3.466

3.  Progressive transformation of germinal centers and nodular lymphocyte predominance Hodgkin's disease: a comparative immunohistochemical study.

Authors:  P L Nguyen; J A Ferry; N L Harris
Journal:  Am J Surg Pathol       Date:  1999-01       Impact factor: 6.394

4.  Stat6 is required for mediating responses to IL-4 and for development of Th2 cells.

Authors:  M H Kaplan; U Schindler; S T Smiley; M J Grusby
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

5.  The transcription factor c-Maf controls the production of interleukin-4 but not other Th2 cytokines.

Authors:  J I Kim; I C Ho; M J Grusby; L H Glimcher
Journal:  Immunity       Date:  1999-06       Impact factor: 31.745

6.  Expression of the T-cell transcription factors, GATA-3 and T-bet, in the neoplastic cells of Hodgkin lymphomas.

Authors:  Cigdem Atayar; Sibrand Poppema; Tjasso Blokzijl; Geert Harms; Marcel Boot; Anke van den Berg
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

Review 7.  Hodgkin's lymphomas: classification, diagnosis, and grading.

Authors:  N L Harris
Journal:  Semin Hematol       Date:  1999-07       Impact factor: 3.851

8.  Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.

Authors:  Tomás Alvaro; Marylène Lejeune; Ma Teresa Salvadó; Ramón Bosch; Juan F García; Joaquín Jaén; Alison H Banham; Giovanna Roncador; Carlos Montalbán; Miguel A Piris
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

9.  Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.

Authors:  M Chesi; P L Bergsagel; O O Shonukan; M L Martelli; L A Brents; T Chen; E Schröck; T Ried; W M Kuehl
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

10.  Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease.

Authors:  B Falini; B Bigerna; L Pasqualucci; M Fizzotti; M F Martelli; S Pileri; A Pinto; A Carbone; S Venturi; R Pacini; G Cattoretti; E Pescarmona; F Lo Coco; P G Pelicci; I Anagnastopoulos; R Dalla-Favera; L Flenghi
Journal:  Blood       Date:  1996-01-15       Impact factor: 22.113

View more
  6 in total

1.  Effects of lymphocyte profile on development of EBV-induced lymphoma subtypes in humanized mice.

Authors:  Eun Kyung Lee; Eun Hye Joo; Kyung-A Song; Bongkum Choi; Miyoung Kim; Seok-Hyung Kim; Sung Joo Kim; Myung-Soo Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-05       Impact factor: 11.205

2.  Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells.

Authors:  Paul Greaves; Andrew Clear; Andrew Owen; Sameena Iqbal; Abigail Lee; Janet Matthews; Andrew Wilson; Maria Calaminici; John G Gribben
Journal:  Blood       Date:  2013-09-04       Impact factor: 22.113

3.  T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications.

Authors:  Claudio Fozza; Maurizio Longinotti
Journal:  Adv Hematol       Date:  2010-10-12

Review 4.  Hodgkin lymphoma: an update on its biology with new insights into classification.

Authors:  Haresh Mani; Elaine S Jaffe
Journal:  Clin Lymphoma Myeloma       Date:  2009-06

Review 5.  The Grey Zones of Classic Hodgkin Lymphoma.

Authors:  Jan Bosch-Schips; Massimo Granai; Leticia Quintanilla-Martinez; Falko Fend
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

6.  CD57+ T-cells are a subpopulation of T-follicular helper cells in nodular lymphocyte predominant Hodgkin lymphoma.

Authors:  Ahmad Sattarzadeh; Arjan Diepstra; Bea Rutgers; Anke van den Berg; Lydia Visser
Journal:  Exp Hematol Oncol       Date:  2015-09-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.